Cover Image

From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure

Imatinib is a targeted cancer therapy that has significantly improved the care of patients with chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST). However, it has been shown that the recommended dosages of imatinib are associated with trough plasma concentration (Cmin) lower t...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sylvain Goutelle (Author), Monia Guidi (Author), Verena Gotta (Author), Chantal Csajka (Author), Thierry Buclin (Author), Nicolas Widmer (Author)
Format:	Book
Published:	MDPI AG, 2023-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
by: Thierry Buclin, et al.
Published: (2020)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
by: Sylvain Goutelle, et al.
Published: (2022)

Population Pharmacokinetics in Oncology and Its Clinical Applications
by: Nicolas Widmer, et al.
Published: (2024)

Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective
by: Myriam Briki, et al.
Published: (2023)

Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin
by: Justine Heitzmann, et al.
Published: (2022)

Model‐based meta‐analysis of salbutamol pharmacokinetics and practical implications for doping control
by: Perrine Courlet, et al.
Published: (2022)

"Hard" Drug Repurposing for Precision Oncology: The Missing Link?
by: Pan Pantziarka, et al.
Published: (2018)

Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study
by: Imke H. Bartelink, et al.
Published: (2021)

Precision Medicine in Oncology
by: Andrea Lunardi
Published: (2019)

Heterogeneity in precision oncology
by: Bartłomiej Tomasik, et al.
Published: (2024)

Reinforcement learning and Bayesian data assimilation for model‐informed precision dosing in oncology
by: Corinna Maier, et al.
Published: (2021)

Combination Therapy With Rapamycin and Low Dose Imatinib in Pulmonary Hypertension
by: Yinan Shi, et al.
Published: (2021)

Population pharmacokinetics of apixaban in a real‐life hospitalized population from the OptimAT study
by: Frédéric Gaspar, et al.
Published: (2023)

Advances in Precision Medicine Oncology
Published: (2021)

Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics
by: Jeffry Adiwidjaja, et al.
Published: (2020)

Moving the needle for oncology dose optimization: A call for action
by: Karthik Venkatakrishnan, et al.
Published: (2024)

Strategies for clinical dose optimization of T cell-engaging therapies in oncology
by: Kathryn Ball, et al.
Published: (2023)

Moving the needle for oncology dose optimization: A call for action
by: Karthik Venkatakrishnan, et al.
Published: (2024)

Editorial: Oral Oncology: From Precise Surgery to Precision Medicine and Surgery
by: Zuzana Saidak, et al.
Published: (2022)

Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
by: Kim Dao, et al.
Published: (2020)

Role of pharmacometrics and systems pharmacology in facilitating efficient dose optimization in oncology
by: Priya Jayachandran, et al.
Published: (2023)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
by: Ronan Swords, et al.
Published: (2009)

Precision Oncology and Cancer Biomarkers Issues at Stake and Matters of Concern
Published: (2022)

Precision Oncology and Cancer Biomarkers Issues at Stake and Matters of Concern /
Published: (2022)

Precision Oncology and Cancer Biomarkers Issues at Stake and Matters of Concern
Published: (2022)

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing
by: Hui-Yin Yow, et al.
Published: (2022)

Ethics of umbrella and basket trials in precision oncology
by: Karolina Strzebonska
Published: (2022)

Model-Informed Precision Dosing
Published: (2023)

Exploiting DNA Damage Response in the Era of Precision Oncology
Published: (2020)

DNA-protein biomarkers for immunotherapy in the era of precision oncology
by: Binnari Kim, et al.
Published: (2021)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
by: Hyacinthe Johnson-Ansah, et al.
Published: (2022)

Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing
by: Zachary L. Taylor, et al.
Published: (2023)

Optimizing Precision Medicine for Public Health
by: Gemma A. Bilkey, et al.
Published: (2019)

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug-drug interaction predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2024)

Imatinib induced lichen planus
by: R Sudha, et al.
Published: (2011)

Profile of imatinib in pediatric leukemia
by: Burke MJ
Published: (2014)

Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib
by: Pantazi D, et al.
Published: (2019)

Pharmacometric Analysis of Intranasal and Intravenous Nalbuphine to Optimize Pain Management in Infants
by: Miriam Pfiffner, et al.
Published: (2022)

Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development
by: Wei Gao, et al.
Published: (2024)

Molecular Tumour Boards and Precision Medicine in Czech Oncology Centres
Published: (2022)